How Much Does CJC-1295/Ipamorelin Cost in Miami
STEP-1 Trial (Semaglutide 2.4 mg, N=1,961) The STEP-1 trial published in the New England Journal of Medicine reported that among participants receiving semaglutide 2.4 mg subcutaneously once weekly, nausea occurred in 44.2%, diarrhea in 29.7%, vomiting in 24.5%, and constipation in 24.1%, compared to 16.0%, 15.9%, 6.8%, and 11.1% with placebo, respectively [3]
This makes intuitive sense but isnt validated
Patients who prefer less frequent dosing or who have trouble remembering to take daily medication may prefer injections
We also lose some lean mass but this isnt necessarily a bad thing, nor does it always mean were losing muscle
This effect, known as delayed gastric emptying, is a feature, not a bug